We also tested SMYD3 abundance in a genetically engineered mouse model that recapitulates the development of human lethal prostate adenocarcinoma and metastasis through MYC overexpression and loss of Pten in prostatic luminal epithelial cells (Hoxb13-MYC+/− Hoxb13-Cre+/−PtenFl/Fl, or BMPC mice) (32). The gene discussed is SMYD3; the disease is prostate adenocarcinoma.